The Saint Luke’s Cancer Institute (SLCI) research program assures access to an extensive range of studies in many cancer specialties. Oncology patients treated at Saint Luke’s Health System metro facilities have the opportunity to participate in disease-specific clinical studies. These include National Cancer Institute Cooperative Research Group Trials, pharmaceutical industry-sponsored research, and investigator-initiated trials.
Through the evaluation of promising investigational treatments from these clinical studies, Saint Luke’s oncology patients and their physicians are provided options for care that otherwise would not be available. SLCI partners with major pharmaceutical and biotech companies as well as prominent academic and medical research institutions throughout the United States.
Our lung cancer research portfolio expanded significantly under the leadership of Janakiraman Subramanian, M.D., M.P.H. We have opened numerous clinical trials focusing on combined chemotherapy and immunotherapy approaches for the treatment of non-small cell lung cancer. We have also initiated studies looking at blood markers that may help differentiate benign from malignant lung nodules identified in lung cancer screening CT scans.
Gary Johnson, M.D., joined Saint Luke’s Cancer Institute as director of gynecologic oncology in late 2015. He brings many years of academic experience and research and is quickly establishing an active research program in gynecologic oncology.
In 2015, we:
- Focused on expanding the number of clinical trials available for patients across the spectrum of cancers
- Doubled the number of active industry-sponsored clinical trials when compared with 2014
- Expanded access at multiple metro sites in order to allow patients to participate in clinical trials closer to their homes
The opening of Saint Luke’s Cancer Institute on the campus of Liberty Hospital allowed 20 patients to participate in clinical trials at Liberty Hospital. In addition, we continue to enroll significant numbers of patients at Saint Luke’s East Hospital and Saint Luke’s South Hospital as well as Saint Luke’s Hospital of Kansas City. These efforts allowed us to maintain an accrual rate of over 6 percent of all new cancer patients, significantly above the national average. Breast cancer remains a focus of our research and was the leading cancer for clinical trial enrollment in 2015. Saint Luke’s patients helped contribute to practice-changing studies in triple negative breast cancer as well as improving targeted therapies for estrogen-dependent breast cancer.
For more information about Saint Luke's Cancer Institute research, call 816-932-2677.
03/30/2017 - 6:00pmGilda's Club Kansas City
This educational program gives people with multiple myeloma and their caregivers an opportunity to hear John Killip, a trained Journey Partner, share his personal experience of living with multiple myeloma and having an autologous stem cell transplant. You will also learn about helpful resources and the importance of considering a transplant.
04/03/2017 - 6:00pmGilda's Club Kansas City
Living with cancer, being a caregiver, or experiencing grief can be exhausting and stressful. Take time for yourself as we come together for relaxation, friendship and support. Learn to use mind-body techniques, such as deep breathing, mindfulness, and meditation, to help gain control over anxiety, reduce stress and relax.
04/06/2017 - 3:00pmSaint Luke's Cancer Institute
Feeling stressed, overwhelmed, and out-of-balance? Looking to explore purpose and meaning? Join Saint Luke's Cancer Institute's Supportive Services to learn mindful approaches for stress reduction, pain management, emotional and physical relief. This is a free support group open to Saint Luke's Cancer Institute patients, families, and caregivers.